Piramal Pharma Solutions launches ADCelerate, a rapid and integrated approach to bring ADCs to IND

  • ADCelerate provides appropriate Phase I drug substance and drug product for Investigational New Drug (IND) submission
  • Accelerates lead times, allowing faster delivery to clinic patients
  • From project initiation to GMP pharmaceutical product in as little as 12 months

Mumbai, India, October 12, 2022 /PRNewswire/ — Piramal Pharma Solutions, a market-leading, patient-centric contract development and manufacturing organization (CDMO), has announced the launch of Acceleratea brand new solution for antibody-drug conjugate drug development that accelerates development timelines from initial clinical supply of drug substance and drug product.

With Accelerate, Piramal Pharma Solutions (PPS) provides fully developed manufacturing processes for Antibody-Drug Conjugate Drug Substance and Lyophilized Drug Product, all in as little as twelve months. The program includes qualified and appropriate Phase I analytical methods to support batch release and stability studies for the drug substance and drug product, as well as initial drug substance and product stability data (six months). medicinal product (one month).

Peter DeYoungChairman and CEO, Piramal Pharma Solutions said, “As a CDMO serving the biopharmaceutical industry, we recognize that speed is important. Getting our clients to the clinic as quickly as possible without compromising quality supports our patient-centric philosophy. Accelerate is a strong example of this principle put into practice. By leveraging our capabilities and expertise in ADCs and Sterile Fill/Finish, we are able to shorten lead times while maintaining the highest quality standards.”

The accelerated deadlines Accelerate Deliveries are made possible by PPS’s extensive experience in solving antibody-drug conjugate problems, as well as the company’s expertise in manufacturing freeze-dried drug products. Although based on a standard process, all Accelerate programs are tailored to each client’s project scope.

To learn more about Acceleratecontact our antibody-drug conjugation experts directly at [email protected].

About Piramal Pharma Solutions:

Piramal Pharma Solutions (PPS) is a contract development and manufacturing organization (CDMO) offering end-to-end development and manufacturing solutions across the entire drug lifecycle. We serve our customers through an integrated global network of facilities in North America, Europeand Asia. This enables us to offer a full range of services, including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial API supply and finished dosage forms. We also offer specialty services such as the development and manufacturing of high potency APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent oral solid drug products. PPS also offers biologics development and manufacturing services, including vaccines, gene therapies and monoclonal antibodies, made possible through Piramal Pharma Limited’s investment in Yapan Bio Private Limited. Our track record as a trusted service provider with experience in various technologies makes us a partner of choice for innovators and generic companies around the world.

For more information, please visit: piramalpharmasolutions.com | Twitter | LinkedIn

About Piramal Pharma Ltd.

Piramal Pharma Limited (PPL) offers a differentiated product and service portfolio through end-to-end manufacturing capabilities at 15 global facilities and a global distribution network of over 100 countries. PPL comprises: Piramal Pharma Solutions (PPS), an integrated development and contract manufacturing organization; Piramal Critical Care (PCC), a Complex Hospital Generics company, and India Consumer Healthcare company, selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through an integrated global network of facilities throughout the drug lifecycle to innovator and generic companies. PCC’s portfolio of complex hospital products includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable analgesics and anesthetics, injectable anti-infectives and other therapies. The Indian Consumer Healthcare business is among the major players in the India in personal care, with established brands in the Indian consumer healthcare market. Additionally, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020the company received an investment in growth shares from the Carlyle Group.

For more information visit: www.piramal.com/pharma | Facebook | Twitter | LinkedIn

For media queries:

For investors:

Rajiv Banerjee | Business communication

Gagan Borana | Investor relations and sustainable development

[email protected]

[email protected]

Logo- https://mma.prnewswire.com/media/1919803/ADCelerate.jpg
Photo – https://mma.prnewswire.com/media/1919834/Piramal_Pharma_Solutions_CEO.jpg
Logo- https://mma.prnewswire.com/media/1726186/Piramal_Pharma_Solutions_Logo.jpg

SOURCEPiramal Pharma Solutions

Comments are closed.